<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535860</url>
  </required_header>
  <id_info>
    <org_study_id>CS 82-000-04</org_study_id>
    <secondary_id>I2Y-MC-GHFE</secondary_id>
    <nct_id>NCT00535860</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) in Comparison to Subcutaneous Injection of Forteo in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransPharma Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>TransPharma Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical efficacy, safety, and tolerability of
      ViaDerm-shPTH [1-34] transdermal delivery in comparison to subcutaneous injection of
      rhPTH[1-34] following 3-month treatment in postmenopausal women with Osteoporosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to endpoint 96 days in procollagen 1 N-terminal propeptide (P1NP)</measure>
    <time_frame>Baseline, 96 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-terminal telopeptide of type I collagen (CTX-1.)</measure>
    <time_frame>Baseline, 96 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hPTH (1-34) Pharmacokinetic AUC of ViaDerm-hPTH (1-34) and teriparatide SC.</measure>
    <time_frame>Baseline, 96 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of hPTH (1-34) AUC of transdermal treatment and subcutaneous injection</measure>
    <time_frame>Baseline, 96 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of hPTH (1-34) Cmax of transdermal treatment and subcutaneous injection</measure>
    <time_frame>Baseline, 96 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hPTH (1-34) Pharmacokinetic Cmax of ViaDerm-hPTH (1-34) and teriparatide SC.</measure>
    <time_frame>Baseline, 96 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with serum total calcium above the upper limit of normal range</measure>
    <time_frame>Over 96 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with serum total calcium more than 1 mg/dl above the upper limit of normal range</measure>
    <time_frame>Over 96 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hPTH (1-34) specific antibody immune response</measure>
    <time_frame>Baseline, 96 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Draize score for erythema and edema</measure>
    <time_frame>Over 96 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) pain assessment</measure>
    <time_frame>Over 96 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>50 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ViaDerm transdermal delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add Via-Derm transdermal delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>Daily for 96 days</description>
    <arm_group_label>50 mcg</arm_group_label>
    <arm_group_label>80 mcg</arm_group_label>
    <arm_group_label>20 mcg</arm_group_label>
    <other_name>Forteo</other_name>
    <other_name>Forsteo</other_name>
    <other_name>LY333334</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusive Criteria:

          -  Post-menopausal women aged between 55 to 85 years (inclusive)

          -  Posterior-Anterior lumbar vertebral and/or femoral neck BMD T-score by DXA â‰¤-2.5 SD.

          -  Have normal serum PTH, thyroid stimulating hormone (TSH) (only for patients treated
             with thyroid hormone), and prolactin values.

        Main Exclusive Criteria:

          -  Subjects who have a clinical significant or unstable medical or surgical condition
             that may preclude safe and complete study participation

          -  Current diagnoses of disorders known to affect bone metabolism including
             hyperthyroidism, hyperparathyroidism, osteomalacia, or Paget's disease

          -  Prior osteoporosis treatment with fluoride or strontium at any time; or any IV
             treatment with bisphosphonates in the past or oral bisphosphonate for more than 1
             month in the past 24 months prior to randomization.

          -  Any condition or disease that may interfere with the ability to have, or to evaluate a
             DXA scan
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Efrat Kochba, MD</last_name>
    <role>Study Director</role>
    <affiliation>TransPharma-Medical Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osteocentrum FN</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteocentrum 3 .Interni Klinika 1. LFUK a VFN</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Research Center</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Department of Orthopedic</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Gyula Hospital Department of Rheumatology</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Andras Hospital-Heviz</name>
      <address>
        <city>Heviz</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Ferenc Hospital Department of Rheumatology</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yafe Medical Center - Endocrinology dep</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center Osteoporosis Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2007</study_first_submitted>
  <study_first_submitted_qc>September 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>July 9, 2009</last_update_submitted>
  <last_update_submitted_qc>July 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Efrat Kochba</name_title>
    <organization>TransPharma Medical Ltd.</organization>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Transdermal</keyword>
  <keyword>hPTH(1-34)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

